- Home
- / Sucampo Pharmaceuticals
Sucampo Pharmaceuticals
Revenue
$230.1 M
FY, 2016
Sucampo Pharmaceuticals Summary
Company summary
- Overview
- Sucampo Pharmaceuticals is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs.
- Type
- Subsidiary
- Status
- Active
- Founded
- 1996
- HQ
- Rockville, MD, US | view all locations
- Website
- http://sucampo.com
- Cybersecurity rating
- Sectors
LocationsView all
7 locations detected
Rockville, MD HQ
United States
805 King Farm Blvd #550
Chiyoda, Tokyo
Japan
NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
Chuo Ward, Hyogo Prefecture
Japan
Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
Kita Ward, Osaka Prefecture
Japan
Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
Sanda-shi, Hyōgo-ken
Japan
4-1 Techno-Park
Zug, Zug
Switzerland
22 Baarerstrasse
Sucampo Pharmaceuticals Financials
Summary financials
- Revenue (Q3, 2017)
- $61.3M
- Gross profit (Q3, 2017)
- $43.8M
- Net income (Q3, 2017)
- $10.4M
- Cash (Q3, 2017)
- $75.0M
- EBIT (Q3, 2017)
- $21.2M
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension